Last reviewed · How we verify

NCT05213039: cp

Validity and Reliability of the the Timed 360° Turn Test

Completed Last updated 20 March 2024
What this trial tests

trial testing assessments in Cerebral Palsy in 91 participants. Completed in 15 March 2024.

Timeline
15 July 2022
Primary endpoint
15 March 2024
15 March 2024

Quick facts

Lead sponsorKahramanmaras Sutcu Imam University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment91
Start date15 July 2022
Primary completion15 March 2024
Estimated completion15 March 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Kahramanmaras Sutcu Imam University

Who can join

Adults 7 to 18, any sex, with Cerebral Palsy or Gait, Spastic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cerebral Palsy (CP) is a non-progressive neurodevelopmental disorder that starts in the early stages of life, causes activity limitation, and consists of movement and posture deficiencies. Children with CP usually have difficulties in mobility, transfer and social participation due to many motor and sensory disorders such as muscle weakness, decreased postural control, balance, spasticity. Many children with CP have difficulty in balancing independently, walking, walking on hills/uneven ground, and performing daily physical functions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of assessments

Trials testing the same drug.

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

Other Kahramanmaras Sutcu Imam University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05213039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing